Protalix to present Phase I PRX-115 data in late-breaking poster at ACR Convergence 2024

Protalix BioTherapeutics, Inc.

PRX-115 is a recombinant PEGylated uricase for uncontrolled gout treatment.
Data from Phase I trial will be presented at ACR Convergence 2024 (Nov 14-19, Washington, D.C.).
Poster session: Monday Nov 18, 10:30 AM-12:30 PM EST; abstract number L05.
Abstract available on ACR abstracts website; poster to be posted on Protalix website.
No clinical results disclosed; presentation details only.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.